Aprotinin reduces the IL-8 after coronary artery bypass grafting

Isbir C., Dogan R., Demircin M., Yaylim I., Pasaoglu I.

CARDIOVASCULAR SURGERY, vol.9, no.4, pp.403-406, 2001 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 9 Issue: 4
  • Publication Date: 2001
  • Doi Number: 10.1016/s0967-2109(01)00011-4
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.403-406
  • Istanbul University Affiliated: Yes


The effect of aprotinin, a protease inhibitor, on myocardial interleukin-8 (IL-8) production after ischemia-reperfusion injury was investigated. Twenty patients who had elective coronary artery bypass grafting were included in this study, Patients were randomly divided into two groups (n = 10 in each). Group A patients received high dose aprotinin (20,000 IU/kg as pretreatment followed by 7500 IU/kg for 6 h) and Group B patients received normal saline as a control. Serum IL-8 levels after the termination of cardiopulmonary bypass (CPB) showed a significant improvement in aprotinin treated group compared to control group (70+/-42.6 vs 360.71+/-87.9 ng/ml) (P<0.005). Levels were also significantly higher at post-operative 24th hour in patients who did not received aprotinin (340.16+/-92.10 vs 96.13+/-34.33 ng/ml). However at post-operative 48th hour levels were again higher in control (untreated) group, but the difference was not statistically significant (78.8+/-34.4 vs 42.8+/-9.29 ng/ml),